Distribution of zolmitriptan into the CNS in healthy volunteers: A positron emission tomography study

Drugs in R and D

Volumn 6, Issue 3, 2005, Pages 139-147

  Wall, Anders ^a   Kågedal, Matts ^b   Bergström, Mats ^a   Jacobsson, Eva ^c   Nilsson, Dag ^b   Antoni, Gunnar ^a   Frändberg, Pernilla ^a   Gustavsson, Sven Åke ^a   Låangstr̈om, Bengt ^a   Yates, Roger ^d  

^a Uppsala Imanet AB   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c IQVIA   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; CARBON MONOXIDE; CARBONYL DERIVATIVE; OXYGEN 15; RADIOACTIVE MATERIAL; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; TRACER; ZOLMITRIPTAN;

ADULT; ARTICLE; BRAIN BLOOD VOLUME; BRAIN REGION; CALCULATION; CENTRAL NERVOUS SYSTEM; CIRCULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG INFUSION; DRUG UPTAKE; FEMALE; HEALTH STATUS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; KINETICS; MALE; NEUROANATOMY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TIME; VOLUNTEER;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; BRAIN; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; OXAZOLIDINONES; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN AGONISTS; TISSUE DISTRIBUTION; TRYPTAMINES;

EID: 22244480049     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506030-00002     Document Type: Article

References (24)

1. Jansen I, Edvinsson L, Mortensen A, et al. Sumatriptan is a potent vasoconstrictor of human dural arteries via a 5-HT1-like receptor. Cephalalgia 1992; 12 (4): 202-5
2. Caekebeke JF, Ferrari MD, Zwetsloot CP, et al. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology 1992; 42 (8): 1522-6
3. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine? Pain 1996; 67: 355-9
4. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997; 17: 153-8
5. 1B/1D agonist for migraine. Cephalalgia 1997; 17 Suppl. 18: 4-14
6. Cumberbatch MJ, Hill RG, Hargreaves RJ. The effects of 5 HT1A, 5 HT1B and 5 HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Eur J Pharmacol 1998; 362: 43-6
7. Uemura N, Charlesworth B, Onishi T, et al. Zolmitriptan is detectable in plasma 2 to 5 minutes after administration by nasal spray [abstract]. Headache 2003; 43 (5): S159
8. Kågedal M, Duvauchelle T, Hovsepian L, et al. Zolmitriptan demonstrates good pharmacokinetic consistency between and within individuals following intranasal administration. Br J Clin Pharmacol 2004; 57 (5): 679-80
9. Yates R, Nairn K, Dixon R, et al. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharmacol 2002; 42: 1237-43
10. Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: a review of its use in migraine. Drugs 1999; 58(2): 347-74
11. Bergstr̈om M, Grahńen A, Låangström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003; 59: 357-66
12. Learned-Coughlin SM, Bergström M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003; 54 (8): 800-5
13. Hartvig P, Bergström M, Antoni G, et al. Positron emission tomography and brain monoamine neurotransmission: entries for study of drug interactions. Curr Pharm Des 2002; 8 (16): 1417-34
14. Gefvert O, Lundberg T, Wieselgren I-M, et al. D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001; 11 (2): 105-10
15. Gefvert O, Bergström M, Långström B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of que-tiapine (Seroquel) in patients with schizophrenia. Psycho-pharmacology (Berl) 1998; 135: 119-26
16. 11C]zanamivir following administration as an intranasal spray: evaluation with positron emission tomography. Clin Pharmacokinet 1999; 36 Suppl. 1: 33-9
17. 11C]-zolmitriptan assessed by positron emission tomography. Cephalalgia 2005. In press
18. 11C-carbamoyl compounds. J Org Chem 2002; 67 (11): 3687-92
19. Gawel M, Aschoff J, May A, et al. Zolmitriptan 5mg nasal spray: efficacy and onset of action in the acute treatment of migraine: results from phase 1 of the REALIZE study. Headache 2005 Jan; 45 (1): 7-16
20. Anderson JL. A rapid and accurate method to realign PET scans utilizing image edge transformation. J Nucl Med 1995; 36 (4): 657-69
21. Dodick D, Brandes J, Elkind A, et al. The speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute management of migraine [abstract]. Headache 2004; 44 (5): 469
22. Hughes AM, Dixon R, Dane A, et al. Effects of zolmitriptan (Zomig™) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine. Cephalalgia 1999; 19: 100-6
23. 1B/1D receptor agonists. Proc Natl Acad Sci USA 2004; 101 (12): 4274-79
24. Syrett N, Abu-Shakra S, Yates R. Zolmitriptan nasal spray: advances in migraine treatment. Neurology 2003; 61 (8 Suppl. 4): S27-30